March 2nd, 2024
This conference has already taken place.
Description
The burden of liver disease and liver cancer is expected to further increase in the years to come. Given new updates in guidelines and practice management, we aim to provide awareness and education for practitioners to manage all aspects of care (gap in knowledge, gap in management). Topics to be discussed include endohepatology, novel therapies in HCC, bleeding risk in patients with cirrhosis, updates in viral hepatitis, AI in healthcare/hepatology, GLP-1s in fatty liver disease, alcohol in the COVID era, and the future of transplantation.
The Ohio State University Wexner Medical Center is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Dates and Times
Start: 3/2/2024 7:50 AM
End: 3/2/2024 2:00 PM
Objectives
At the conclusion of this activity, learners will be able to:
1) Describe novel therapeutics and their indications in endohepatology
2) Explain utility of GLP-1 drugs in the fatty liver population
3) Define treatment paradigms for hepatitis B and hepatitis D
4) Describe new medication regimens for the treatment of HCC
Agenda
.png)
Pricing
| Tier | Price |
|---|---|
| This is a free event | $0.00 |
Speakers
Location
James Cancer Hospital and Solove Research Institute, Room L035
460 W 10th Ave
Room L035
Columbus, OH 43210
Accreditation Statement
The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Ohio State University designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.